Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Recruiting · NCT06376916 · Interventional (participants receive a specific treatment) · Lead sponsor: Wake Forest University Health Sciences
View the official record on ClinicalTrials.gov →Interventions studied
Magnesium Sulfate 2 GMagnesium Sulfate 4 GSaline
What this trial is about
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age \> 18 years or older
- Able to provide informed consent
- Primary diagnosis AFF RVR greater than or equal to 120 bpm
- Diltiazem as rate control agent
- English speaking
Exclusion criteria
- Hemodynamically unstable patients (SBP \<90, MAP \<65)
- Impaired consciousness
- End stage renal disease on hemodialysis or peritoneal dialysis
- Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
- Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
- Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response
- Acute myocardial infarction
- Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)
- Contraindications to magnesium sulfate (including myasthenia gravis)
- Allergy or sensitivity to any study drugs
- Previously enrolled in this trial during a different patient encounter
- Withdrew from study
Where it is running
1 location listed across 1 US state.
- Advocate Christ Medical Center Emergency Department (ACMC ED) - Oak Lawn, Illinois, United States